Alembic gets USFDA nod for generic skin treatment cream

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Desonide Cream, 0.05 per cent, of Padagis US LLC. Desonide Cream, 0.05 per cent, is a low-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/96hGYPV
via IFTTT